EUVIMEDEUVIMED entdecken
Crossref

A Dual-Action CXCR4-Targeted Peptide−Drug Conjugate Engineered to Enhance Antitumor Efficacy and Mitigate Myelosuppression in Pancreatic Cancer

Ke Zhu, Xuanxin Liu, Dapeng Li, Tao Wang, Tao Wen iD, Xiaocui Fang iD, Yanlian Yang iD, Jian Liu, Jie Meng, Chen Wang iD, Haiyan Xu iD

Molecular Pharmaceutics · 2026

DOI: 10.1021/acs.molpharmaceut.6c00292 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Ke Zhu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Basic Medical Sciences & School of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing100005, Ch…. Hauptthemen laut MEDLINE: Receptors, CXCR4, Pancreatic Neoplasms, Deoxycytidine, Peptides. Die Arbeit nennt 51 Literaturangaben. Gefördert von: Chinese Academy of Sciences, Natural Science Foundation of Beijing Municipality, Chinese Academy of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gemcitabine (GEM) is a first-line therapeutic option for pancreatic cancer; however, it has low efficacy due to rapidly developed drug resistance and severe dose-limiting myelosuppression. To enhance its therapeutic effect, this study developed a novel peptide−drug conjugate using a CXCR4 antagonistic peptide as the targeting head and gemcitabine as the drug payload, based on the characteristics of pancreatic tumor cells highly expressing CXCR4 that mediates immunosuppression and tumor progression through interaction with its specific ligand CXCL12. The therapeutic effect of the conjugate (P12-GEM) was investigated using pancreatic ductal adenocarcinoma cell lines and an orthotopic pancreatic cancer mouse model. Its myelosuppressive effect was assessed from the perspective of hematological toxicity profiles. The results showed that P12-GEM maintained a cell-killing capability comparable to that of GEM while effectively inhibiting the phosphorylation of Erk and P38, thereby reducing CXCL12-mediated tumor cell migration and adhesion to stromal cells. In a tumor-bearing mouse model, P12-GEM demonstrated superior antitumor efficacy compared to GEM and significantly extended animal survival. Moreover, P12-GEM reduced the proportion of tumor-associated macrophages and increased the infiltration of CD8+ T cells in the tumor microenvironment without reducing platelet and white blood cell counts in the peripheral blood. In summary, P12-GEM possesses dual functions of CXCR4 antagonism and tumor cell killing, contributing to reversal of the immunosuppressive microenvironment and alleviation of myelotoxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, CXCR4Pancreatic NeoplasmsDeoxycytidinePeptidesCarcinoma, Pancreatic DuctalAnimalsMiceHumansCell Line, TumorGemcitabineChemokine CXCL12Xenograft Model Antitumor AssaysCell MovementFemaleTumor MicroenvironmentAntineoplastic Agents

Stichwörter der Autor:innen

CXCR4 antagonistgemcitabinepancreatic cancerpeptide−drug conjugatetumor microenvironment

Substanzen

Receptors, CXCR4DeoxycytidineGemcitabineChemokine CXCL12PeptidesCXCR4 protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Institute of Basic Medical Sciences & School of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing100005, China.
  • CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, University of Chinese Academy of Sciences, Beijing100049, China.
  • State Key Laboratory of Advanced Medical Materials and Devices, Institute of Basic Medical Sciences, Tianjin Institutes of Health Science, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin301600…
  • Beijing Key Laboratory of Key Technologies for Natural Drug Delivery and Novel Formulations, Beijing102600, China.

ORCID-Profile: Tao Wen, Xiaocui Fang, Yanlian Yang, Chen Wang, Haiyan Xu

Förderung

  • Chinese Academy of Sciences
  • Natural Science Foundation of Beijing Municipality
  • Chinese Academy of Medical Sciences
  • National Key Research and Development Program of China

Zitieren

APA

Zhu, K., Liu, X., Li, D., Wang, T., Wen, T., Fang, X., Yang, Y., Liu, J., Meng, J., Wang, C., & Xu, H. (2026). A Dual-Action CXCR4-Targeted Peptide−Drug Conjugate Engineered to Enhance Antitumor Efficacy and Mitigate Myelosuppression in Pancreatic Cancer. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.6c00292

Vancouver

Zhu K, Liu X, Li D, Wang T, Wen T, Fang X, et al. A Dual-Action CXCR4-Targeted Peptide−Drug Conjugate Engineered to Enhance Antitumor Efficacy and Mitigate Myelosuppression in Pancreatic Cancer. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.6c00292

BibTeX
@article{Zhu2026,
  author = {Zhu, Ke and Liu, Xuanxin and Li, Dapeng and Wang, Tao and Wen, Tao and Fang, Xiaocui and Yang, Yanlian and Liu, Jian and Meng, Jie and Wang, Chen and Xu, Haiyan},
  title = {A Dual-Action CXCR4-Targeted Peptide−Drug Conjugate Engineered to Enhance Antitumor Efficacy and Mitigate Myelosuppression in Pancreatic Cancer},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  doi = {10.1021/acs.molpharmaceut.6c00292}
}
Kostenlos starten →